Glp 1 T 2d denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for glp1 t2d are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied This GLP-1 for Type 2 Diabetes: Duplicate Therapy

A duplicate-therapy denial means Cigna's system flagged that you are already receiving a medication it considers therapeutically equivalent or in the same drug class as the prescribed GLP-1. This is an automated utilization-management flag and does not necessarily reflect a sound clinical judgment about your individual situation. It frequently arises when a patient is transitioning between agents, using two drugs from the same class for distinct approved indications, or when claims data is stale or incomplete.

## Why It Is Appealable

Not all GLP-1 agents are interchangeable. Within this drug class, different agents carry distinct FDA-approved indications, have meaningfully different clinical profiles, and may be combined with other diabetes medications in ways that are recognized in applicable clinical guidelines (such as those from the American Diabetes Association). If your prescriber has documented a specific clinical reason to use the prescribed agent alongside or instead of another drug, that rationale rebuts the duplicate-therapy classification. The appeal should focus on clinical distinction, not just class membership.

## Federal Appeal Framework

• Internal appeal (ACA §2719 / ERISA §503): A full and fair internal review is your right. Submit your appeal in writing within the deadline on the denial notice.
• Peer-to-peer review: Request that Cigna arrange a peer-to-peer call between your prescriber and Cigna's medical reviewer. This is often the fastest path to resolving a duplicate-therapy flag before a formal appeal.
• External review: If the internal appeal is denied, independent external review is available under ACA §2719 within approximately four months of the denial notice. Expedited review applies if delay poses a serious health risk.

## Documentation to Gather

1. Prescriber's clinical distinction letter: A letter from your prescribing physician explaining why the prescribed GLP-1 is not duplicative — for example, its distinct mechanism, indication, or role in your individualized diabetes management plan. 2. Medication list: A complete, dated list of all current diabetes medications, confirming what is and is not actively being used and for what indication. 3. Clinical records: Chart notes, HbA1c trends, and other relevant labs demonstrating your glycemic control history and why your prescriber determined that this specific agent is appropriate. 4. FDA prescribing labels: For both the newly prescribed agent and any drug Cigna flagged as duplicative, the FDA label's indication and clinical pharmacology sections — to document that the two agents are not the same. 5. Applicable guideline organization reference: A citation to the relevant professional organization's treatment guidelines (e.g., the ADA Standards of Care) for any recommendation supporting the combination or substitution, without quoting specific numbers.

## Criteria-Mapping Structure

Address Cigna's specific duplicate-therapy finding directly: identify the drug Cigna cited as the duplicate, then provide a point-by-point comparison showing the clinical or indication-based distinction your prescriber relied upon. Attach the prescriber letter and relevant label sections as exhibits. A focused, evidence-based rebuttal of the specific duplication claim is far more effective than a general medical-necessity argument.